Clinical Chemistry - Case Study
https://doi.org/10.1093/clinchem/hvae223
A 2-year-old male patient had received a diagnosis of acute myeloid leukemia (subtype: acute myeloblastic leukemia with minimal maturation according to the French-American-British classification) with a high genetic risk profile [i.e., monosomy 7, t(3;17)].
Student Discussion Document (pdf)
Malte Hannich, Uwe Grunwald, Karoline Ehlert, Matthias Nauck, and Carlo Zaninetti
A 2-year-old male patient had received a diagnosis of acute myeloid leukemia (subtype: acute myeloblastic leukemia with minimal maturation according to the French-American-British classification) with a high genetic risk profile [i.e., monosomy 7, t(3;17)]. The child had initially undergone 2 courses of chemotherapy with sequential high-dose cytarabine and mitoxantrone. Because of an early relapse, allogeneic stem cell transplantation was planned, and the patient received a preparative chemotherapy regimen with fludarabine, treosulfan, thiotepa, and antithymocyte globulin. Because of an expected chemotherapy-related worsening of the pre-existing, disease-related thrombocytopenia, strict monitoring of the platelet count was started. In this context, the patient came to the attention of the laboratory due to challenges associated with measurement and interpretation of automated platelet counts.